Post-marketing safety concerns with trofinetide: a disproportionality analysis of the first therapeutic agent for Rett syndrome based on the FDA adverse event reporting system (FAERS)
This study unveils certain potential risks associated with trofinetide in real-world applications. Medical staffs should pay more attention to AEs of patients on the first month.
Authors
- Xihui Yu
- Zhuomiao Lin
- Jiahong Zhong
- Yaofeng Zhang
- Hongbo Fu
Institutions
- Shantou University (CN)
- Meizhou City People's Hospital (CN)
- Second Affiliated Hospital of Shantou University Medical College (CN)
Publication Details
- Journal
- Frontiers in Pharmacology
- Published
- 2026-01-14
- DOI
- https://doi.org/10.3389/fphar.2026.1643906
- Primary Topic
- Genetics and Neurodevelopmental Disorders
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Basic and Applied Basic Research Foundation of Guangdong Province